0.45
+0.061(+15.84%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.42 |
| Day High | 0.45 |
| Day Low | 0.4 |
| 52-Week High | 1.82 |
| 52-Week Low | 0.22 |
| Volume | 511,846 |
| Average Volume | 145,786 |
| Market Cap | 12.51M |
| PE | -0.25 |
| EPS | -1.77 |
| Moving Average 50 Days | 0.52 |
| Moving Average 200 Days | 1.04 |
| Change | 0.06 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $22.41 as of May 09, 2025 at a share price of $0.446. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $11.81 as of May 09, 2025 at a share price of $0.446.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 millio
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 04, 2025 11:00 AM GMT
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 06, 2025 9:05 PM GMT
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of